This article is provided for educational and informational purposes only. All compounds discussed are supplied strictly for laboratory and research use. Vitro Labs products are not for human or animal consumption.
CJC-1295 and Ipamorelin are two of the most-studied research-grade compounds in the growth-hormone secretagogue family, and researchers comparing them often source both from the same supplier so the batches line up cleanly for paired experiments. The two compounds look like they do the same thing on the surface. Both raise growth-hormone output in preclinical research models. Both have been characterized at the receptor level since the early 2000s. But they engage completely different receptors, on different timescales, with different selectivity profiles.
That distinction is the point of this article. CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH). Ipamorelin is a small synthetic compound that mimics ghrelin at a different receptor. Teichman and colleagues (2006) characterized the CJC-1295 binding profile in human research subjects and reported a half-life window of 6 to 10 days for the DAC-modified version (PMID: 16940447). Raun and colleagues at Novo Nordisk (1998) characterized Ipamorelin as a selective GHS-R1a agonist with a clean pharmacology profile in animal models (PMID: 9849822). The two compounds converge on the same downstream output. They just take very different paths to get there.
This comparison reviews each compound at the receptor and signaling level, the published research that distinguishes them, and the structural reasons researchers often pair them in experimental protocols. for laboratory research use only.
Before walking through each compound individually, here is the side-by-side view that most researchers want first. The differences in receptor target, structural class, and circulating half-life are what actually drive experimental design decisions.
| Property | CJC-1295 (with DAC) | Ipamorelin |
|---|---|---|
| Structural class | 30-amino-acid GHRH analog | Synthetic 5-amino-acid compound (5 amino acids) |
| Primary receptor | GHRH receptor (GHRH-R) | Growth hormone secretagogue receptor 1a (GHS-R1a) |
| Endogenous analog | GHRH (growth-hormone-releasing hormone) | Ghrelin (gut-derived hormone) |
| Signaling pathway | Gs / cAMP / PKA | Gq / PLC / IP3 / calcium release |
| Half-life (research models) | ~6 to 10 days (with DAC); ~30 minutes (no DAC) | ~2 hours |
| Selectivity profile | GHRH-R selective; some downstream prolactin signal in some models | GHS-R1a selective; minimal cortisol or prolactin response |
| First characterized | 2005 (DAC technology, ConjuChem) | 1998 (Novo Nordisk, Raun et al.) |
CJC-1295 is a synthetic 30-amino-acid compound modeled on the N-terminal active fragment of human growth-hormone-releasing hormone. the same GHRH that the hypothalamus releases in pulses to signal the anterior pituitary. Native GHRH has a problem from a research-pharmacology standpoint: it clears the bloodstream in minutes, partly because the enzyme dipeptidyl peptidase IV (DPP-IV) chops off the first two amino acids almost immediately. The CJC-1295 scaffold was designed around that problem.
The compound itself includes four amino acid substitutions that make it resistant to DPP-IV cleavage. That alone extends the half-life from minutes to roughly 30 minutes in research models. The bigger change is the DAC tag. short for Drug Affinity Complex. DAC is a small chemical handle that covalently latches the compound onto albumin, the most abundant protein in blood.
Once stuck to albumin, the compound stops getting filtered out quickly. Teichman and colleagues (2006) measured the pharmacokinetics in human research subjects and reported the circulating half-life extended to roughly 6 to 10 days with DAC versus minutes without (PMID: 16940447).
CJC-1295 binds the GHRH receptor, a Gs-coupled receptor expressed on somatotrophs in the anterior pituitary. When activated, the receptor turns up intracellular cAMP through adenylate cyclase, which activates protein kinase A (PKA). PKA then triggers the release of stored growth hormone from somatotroph granules. The result, in preclinical research, is sustained elevation of basal GH levels and amplified pulse amplitude over the dosing window.
Importantly, because CJC-1295 works through the same receptor as native GHRH, it preserves the pulsatile architecture of GH release. the hypothalamus still drives the timing, the compound just turns up the volume.
Ipamorelin sits in a different chemical family entirely. It is a small synthetic 5-amino-acid compound. only five amino acids long. designed by researchers at Novo Nordisk in the late 1990s. Raun and colleagues (1998) published the original characterization in European Journal of Endocrinology, reporting that Ipamorelin produced GH release comparable to GHRP-6 in pituitary cell cultures and animal models, but without the cortisol and prolactin response that the older GHRPs produced (PMID: 9849822).
The receptor Ipamorelin binds is GHS-R1a, the same receptor that the gut hormone ghrelin engages. Ghrelin was identified in 1999 by Kojima and colleagues, who isolated it from rat stomach tissue and showed that it bound the orphan receptor researchers had already named GHS-R based on its affinity for earlier synthetic secretagogues (Kojima et al., 1999, PMID: 10604470).
That paper closed the loop on a decade of pharmacology. researchers had been characterizing synthetic ghrelin mimetics like GHRP-6 and Ipamorelin before anyone knew what the endogenous ligand was.
What sets Ipamorelin apart in the published literature is not potency. It is selectivity. The Raun group specifically engineered the 5-amino-acid compound structure to engage GHS-R1a cleanly without measurable affinity for the receptors that drive ACTH/cortisol or prolactin release. In their 1998 paper, growth-hormone output rose substantially after Ipamorelin administration in swine and rat models, while cortisol and prolactin stayed at baseline.
That receptor selectivity is the single feature researchers cite most often when explaining why Ipamorelin remains a workhorse compound in GH-axis research more than 25 years after its discovery.
This is where the comparison gets genuinely interesting. The two compounds converge on the same downstream output. growth hormone release from pituitary somatotrophs. but they take different routes through different receptors using different second messengers.
The GHRH receptor is a class B G-protein-coupled receptor. When CJC-1295 binds, the receptor activates Gs alpha, which turns on adenylate cyclase, which raises intracellular cAMP. cAMP activates PKA. PKA phosphorylates a downstream cascade that culminates in two effects: immediate exocytosis of pre-stored GH granules, and longer-term upregulation of GH gene transcription. This is the textbook GHRH pathway, characterized by Bowers and others through the 1980s and 1990s.
GHS-R1a is a different class of G-protein-coupled receptor. When Ipamorelin binds, GHS-R1a signals primarily through Gq, which activates phospholipase C (PLC). PLC cleaves membrane phospholipids to produce IP3 and DAG. IP3 triggers calcium release from intracellular stores. The calcium spike, combined with DAG-mediated PKC activation, drives somatotroph granule exocytosis. The pathway is faster and more transient than the cAMP route, which is part of why the GH pulse from Ipamorelin is sharper and more pulsatile in preclinical recordings.
The peer-reviewed literature on each compound covers different terrain, partly because of how long each has been studied and partly because of what each was originally developed to investigate.
The defining study on CJC-1295 remains Teichman and colleagues (2006), which characterized the pharmacokinetics and pharmacodynamics in healthy adult research subjects (PMID: 16940447). Subjects received single subcutaneous doses, and researchers tracked both circulating CJC-1295 levels and downstream IGF-1 (an indirect marker of sustained GH-axis activation).
The paper reported the 6 to 10 day circulating half-life that defined the compound’s pharmacology profile, with IGF-1 elevations persisting roughly a week after a single dose. Ionescu and Frohman (2006) followed with a related characterization paper that examined GH pulse architecture under CJC-1295 administration, reporting that the compound preserved pulsatile GH release rather than flattening it (PMID: 16940458).
Raun and colleagues (1998) remains the most-cited Ipamorelin paper for receptor pharmacology and selectivity. The group demonstrated dose-dependent GH release in swine and rat models, with the GH response saturating at concentrations that produced no detectable change in cortisol or prolactin (PMID: 9849822).
For receptor-level characterization, Kojima and colleagues (1999) provided the foundational ghrelin/GHS-R1a paper that grounds all subsequent ghrelin-mimetic research, isolating the endogenous ligand and confirming the receptor pharmacology (PMID: 10604470). Howard and colleagues (1996) had earlier cloned and characterized the GHS-R receptor itself, providing the molecular target framework that the Raun group used to design Ipamorelin’s selectivity profile (PMID: 8688086).
CJC-1295 research has historically focused on duration-of-action and pharmacokinetics. the engineering question of how to sustain GH-axis activation across a longer window. Ipamorelin research has focused on receptor selectivity. the pharmacology question of how to engage one pathway cleanly without spillover into adjacent stress-axis receptors. The two literatures complement each other rather than overlap.
“Ipamorelin is the first GHRP-receptor agonist with a selectivity for GH release similar to that displayed by GHRH.”
, Raun et al. (1998), European Journal of Endocrinology, PMID: 9849822
The structural difference between the two compounds matters for laboratory handling. CJC-1295 is a 30-residue compound with a covalent maleimidopropionic acid linker. Ipamorelin is a synthetic 5-amino-acid compound with non-standard amino acid substitutions designed for protease resistance. These are very different molecules from a stability standpoint.
Both compounds are typically supplied as lyophilized powder in sealed vials. In lyophilized form, compound stability is excellent. research literature on related compounds documents shelf stability of years when stored cold and dry. Once reconstituted in aqueous solution, the picture changes. CJC-1295 with DAC is more stable in solution than the unmodified compound because the albumin-binding mechanism that extends circulating half-life also reduces aggregation tendency in vitro.
Ipamorelin’s small 5-amino-acid compound structure is comparatively resistant to enzymatic degradation but should still be handled with standard cold-chain protocols once reconstituted.
Standard laboratory reconstitution uses bacteriostatic water for compound research protocols requiring multi-use storage, or sterile water for single-use protocols. Diluent selection affects observed stability and should match the experimental design. Vitro Labs supplies USP-grade bacteriostatic water (3ml) as a paired diluent for laboratory reconstitution workflows.
One important wrinkle in any CJC-1295 versus Ipamorelin comparison: there are two versions of CJC-1295 in the published literature, and they have wildly different pharmacology.
The unmodified compound. sometimes called Mod GRF 1-29 or by its tetra-substituted sequence designation. has the four amino acid substitutions that resist DPP-IV cleavage, but no DAC tag. Its half-life is roughly 30 minutes in research models. Because it does not bind albumin, it produces pulsatile GH-axis activation that more closely resembles native GHRH pulsing.
The DAC-modified version is the one that produces the 6 to 10 day half-life Teichman and colleagues characterized (PMID: 16940447). The sustained albumin-bound circulation translates into elevated basal GH and IGF-1 levels across the dosing window rather than discrete pulses.
For research protocols that need pulsatile, short-acting GHRH-receptor activation, the no-DAC version pairs more naturally with Ipamorelin’s similarly short timescale. For research protocols that need steady-state GHRH-axis activation, the DAC version is the engineered tool. The choice depends entirely on the experimental question.
Vitro supplies a CJC-1295 + Ipamorelin 20mg blend precisely because the two compounds appear together so often in the published literature. The pairing has a clear receptor-level rationale.
GHRH and ghrelin are not redundant signals at the pituitary. They are complementary. In preclinical work, simultaneous activation of GHRH-R and GHS-R1a on the same somatotroph produces a GH release response substantially larger than either pathway alone. the two intracellular cascades (cAMP/PKA and PLC/calcium) converge on granule exocytosis from different angles and the effects add rather than cancel. This synergy is what makes the pairing interesting as a research tool rather than a redundancy.
Researchers who pair a GHRH analog with a ghrelin mimetic often choose Ipamorelin specifically because of the clean cortisol and prolactin profile Raun and colleagues documented (PMID: 9849822). Older GHRPs like GHRP-2 and GHRP-6 also engage GHS-R1a but with more spillover into stress-axis signaling. Ipamorelin’s selectivity preserves the cleanliness of the experimental signal.
For researchers comparing the two compounds in parallel experimental designs, handling considerations matter as much as the pharmacology.
Lyophilized vials of either compound are typically stored at refrigeration temperatures (2 to 8°C) for short-term holding, or at -20°C for longer-term storage. Light exposure should be minimized. Reconstituted solutions of either compound are best stored cold and used within the timeframe specified by the analytical certificate for the lot.
For paired-administration research designs, sourcing both compounds from the same supplier. with matched batch-specific Certificates of Analysis. eliminates one variable from the experimental design. Vitro Labs supplies both compounds with batch-specific COAs from Freedom Diagnostics, an ISO-certified independent analytical laboratory. Identity is verified by HPLC and mass spectrometry per batch. Researchers can review the COA before adding either compound to laboratory inventory.
Reconstitution volumes are calculated as research procedures based on the experimental concentration target and the lyophilized mass per vial. The mass-to-volume calculation is a property of the compound and protocol, not a recipe for the operator. For background on diluent selection and reconstitution procedure as a research process, see Vitro’s Research Library.
The choice between CJC-1295 and Ipamorelin. or the decision to pair them. comes down to the experimental question, not a hierarchy of which compound is “better.”
CJC-1295 and Ipamorelin are research compounds. Neither is approved for human consumption by the FDA or equivalent regulatory authorities. Both fall under the research-use-only category for laboratory and analytical research applications, and the marketing context of any sourcing decision should reflect that.
Vitro Labs supplies a curated catalog of research-grade compounds with batch-specific Certificates of Analysis from Freedom Diagnostics. Researchers can review batch documentation through the public COA page before sourcing decisions. For laboratory research use only. Not for human consumption.
Receptor target and signaling pathway. CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH) that binds the GHRH receptor on pituitary somatotrophs and signals through the Gs/cAMP/PKA pathway. Ipamorelin is a synthetic 5-amino-acid compound ghrelin mimetic that binds the growth hormone secretagogue receptor 1a (GHS-R1a) and signals through the Gq/PLC/IP3/calcium pathway. Both pathways converge on growth hormone granule exocytosis from somatotrophs, but they engage different receptors using different intracellular cascades. Raun and colleagues (1998) characterized Ipamorelin’s selective GHS-R1a pharmacology in their original paper (PMID: 9849822).
Roughly 6 to 10 days for CJC-1295 with DAC, compared to roughly 2 hours for Ipamorelin. The difference comes from the Drug Affinity Complex (DAC) tag on CJC-1295, which covalently binds the compound to serum albumin and dramatically slows clearance. Teichman and colleagues (2006) characterized the CJC-1295 with DAC pharmacokinetics in human research subjects and reported the 6 to 10 day window (PMID: 16940447). Ipamorelin clears through standard renal and proteolytic pathways without the albumin-binding mechanism.
Because in preclinical pharmacology studies, Ipamorelin raises growth hormone output without producing measurable increases in cortisol or prolactin. Raun and colleagues (1998) designed the 5-amino-acid compound structure specifically to engage GHS-R1a cleanly while avoiding the receptors that drive stress-axis activation. In swine and rat models, growth hormone release rose substantially after Ipamorelin administration while cortisol and prolactin stayed at baseline (PMID: 9849822). Older ghrelin mimetics like GHRP-6 produced measurable cortisol and prolactin responses in the same model systems.
Because GHRH and ghrelin pathways amplify each other at the pituitary somatotroph level. Simultaneous activation of the GHRH receptor (CJC-1295) and GHS-R1a (Ipamorelin) on the same somatotroph produces a growth hormone release response larger than either pathway alone. The two intracellular cascades. cAMP/PKA from GHRH-R and PLC/calcium from GHS-R1a. converge on granule exocytosis from different angles and the effects add rather than cancel. This synergy is the receptor-level rationale behind paired-administration research designs.
Half-life. Both versions share the four amino acid substitutions that resist DPP-IV cleavage. The difference is whether the compound carries the Drug Affinity Complex (DAC) tag. a maleimidopropionic acid linker that binds the compound to albumin. With DAC, the circulating half-life is roughly 6 to 10 days (Teichman et al., 2006, PMID: 16940447). Without DAC, the half-life is roughly 30 minutes. The two versions produce different GH-axis activation patterns: pulsatile for no-DAC, sustained steady-state for DAC.
It was identified before the endogenous ligand. Howard and colleagues (1996) cloned and characterized the growth hormone secretagogue receptor based on its affinity for earlier synthetic compounds like GHRP-6 (PMID: 8688086). The receptor was considered orphan. known but without an identified natural ligand. until Kojima and colleagues (1999) isolated ghrelin from rat stomach tissue and confirmed it as the endogenous GHS-R1a ligand (PMID: 10604470). Ipamorelin was developed in this window between receptor characterization and ligand identification.
